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Abstract
Background: MicroRNAs (miRNAs) are small endogenous non-coding RNAs with fundamental roles in the regulation of protein
expression that is involved in the pathogenesis of many cancers including breast cancer. Among them is miR-206, whose role as
a tumor suppressor gene has been demonstrated in breast cancer. Consequently, the identification of its putative target in breast
cancer is of practical value.
Methods: In the present study, we have suggested a new approach for the identification of miR-206 target genes with possible role
in breast cancer pathogenesis. We used 15 online tools for the prediction of miR-206 target genes as well as gene expression data
produced by DNA microarray technology.
Results: By combining these two sets of data, we suggested a list of miR-206 target genes with possible involvement in breast cancer.
In addition, we depicted an interaction network including miR-206 and its putative targets.
Conclusions: Considering the complexity of miR-206 interactions with several targets, such in silico analyses would considerably
lessen the work load of laboratory experiments.
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1. Background
As the most frequently diagnosed type of cancer, breast
cancer among women can be classified based on expres-
sion patterns to luminal A, luminal B, Her2+, and triple
negative (TN) subtypes, which are correlated with patients’
survival and prognosis (1). Several researches have focused
on the exploration of gene expression patterns among
these subtypes to find a biologically relevant biomarker in
breast cancer (2-5). The expression pattern analysis of non-
coding RNAs has also been the focus of researchers (6, 7).
Pathway-based expression analysis has further been sug-
gested as a more systematic strategy for biomarker discov-
ery (8, 9). MicroRNAs (miRNAs), as the major regulators of
gene expression, and pathway regulation are thought to
participate in tumorigenesis process by changing the ex-
pression of several mRNA coding genes, non-coding RNA
as well as cancer-related signaling pathways. MiR-206 is
among miRNAs, whose role has been highlighted as a tu-
mor suppressor. It has been the first miRNA detected
in breast cancer. A miR-206-binding site has been found
within the 3’-untranslated region (3’UTR) of estrogen re-
ceptor (ER)-α. ER negative breast cancer cells such as MDA-
MB-231 cells have higher expression of this miRNA com-
pared with ER positive cells such as MCF-7 cells. Notably,
the forced over-expression of this miRNA in triple negative
breast cancer cells has diminished their metastatic poten-
tial and decreased the expression levels of matrix metal-
loproteinase while increased expression of breast cancer
metastatic suppressor (BRMS)-1. Functional studies have
shown Cx43 to be a target of miR-206. Expression analy-
sis in human breast cancer specimens has demonstrated
the associations between miR-206 levels and both lymph
node status and Cx43 expression. While miR-206 signifi-
cantly decreased the proliferation and metastatic poten-
tial of cancer cells, it could not suppress tumor initiation in
a mouse xenograft model due to the contraindicatory roles
of Cx43 during tumorigenesis (10). Its down-regulation in
breast cancer tissues has been associated with increased
tumor size and advanced tumor stage. Up-regulation of
miR-206 in MCF-7 breast cancer cells prevented cell prolif-
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eration and cell growth by the inhibition of the G1/S tran-
sition. MiR-206 has an inhibitory effect on the expression
of cyclinD2 at both the transcript and protein levels. Taken
together, miR-206 has been recognized as a critical tumor
suppressor gene in breast tissues, a probable prognostic
biomarker, or a beneficial target for the treatment of pa-
tients with breast cancer (11).
Based on the complex interaction network between
miRNAs and mRNAs, which is implicated in physiologic
processes and cancer, several studies aimed at predicting
the miRNA targets. However, the valid prediction of miRNA
targets is still problematic. Merging experimental and
computational tools for decoding miRNA functions and
targets has been suggested as an attractive approach in
this regard (12). Consequently, in the present study, we
have suggested a bioinformatics approach for the identifi-
cation of miRNA-206 target genes implicated in breast can-
cer based on miRNA target prediction tools and microarray
data analysis. This miRNA has been chosen based on its ev-
ident role in the suppression of breast cancer and its con-
tribution in the regulation of tumor-associated pathways.
2. Methods
The workflow of data analysis is demonstrated in Fig-
ure 1.
2.1. Breast Cancer Expression Data
mRNA expression profiles for 285 breast cancer sam-
ples and 22 normal tissues were collected from gene ex-
pression omnibus (GEO) repository as series GSE65194 and
GSE45827. The GEO database launched in 2000 by the na-
tional center for biotechnology information (NCBI) incor-
porates gene expression data provided from microarray
technology (13). By entering “breast cancer” and “tran-
scriptome” key words and choosing “Expression profiling
by array” as the filter and the minimum sample size of
100 for datasets, 10 datasets were retrieved. GSE45827 and
GSE65194 datasets with similar array platforms (GPL570)
and inclusion of 4 molecular subtypes of breast cancer (lu-
minal A, luminal B, Her2+ and TN) have been selected for
further analyses. The pipeline applied for the selection of
these datasets is demonstrated in Figure 2.
2.2. Prediction of miRNA-206 Targets from miRNA Prediction
Databases
In this study, systematic miRNA-206 target search was
carried out on 14 prediction databases (Mirwalk, MirMAP,
Mirbase, PITA, Microrna.org conserved, RNA22, MBStar, DI-
ANA, MirTarbase, mirDIP, MirTar2, Mirza G, PACCMIT, Tar-
getscan, TargetSpy) (Table 1).
The fundamental criteria used in some of these pre-
diction databases (for instance TargetScan and DIANA) are
complementarity between miRNA and mRNA in seed re-
gions, folding free energy for the miRNA-mRNA duplex,
and evolutionary conservation (14). In order to increase
the sensitivity of our approach, we chose the mRNAs pre-
dicted as miR-206 target by at least 2 databases out of the
15 databases. A list of candidate mRNAs was selected.
2.3. Experimentally Validated miR-206 Target Genes
Due to the drawbacks associated with the predictions
of miRNA target sites with the bioinformatics tools (15), in
order to find functionally relevant targets in breast cancer,
we searched the literature to find functional studies for the
identification of miR-206 targets in breast cancer as well as
all types of cancer.
2.4. Detection of Differentially Expressed Genes in Breast Cancer
Subtypes
We compared the expression profile of 4 breast cancer
subtype samples with normal samples by GEO2R web
tool (https://www.ncbi.nlm.nih.gov/geo/info/geo2r.html).
Based on Log2-fold change between 2 experimental con-
ditions (LogFC) and adjusted P values calculated by the
software, 300 genes have been chosen in each subtype
with the highest differential expression among tumoral
and normal samples.
2.5. Identification of miR-206 Targets Among Differentially Ex-
pressed Genes in Breast Cancer Subtypes
The R statistical program (16) was applied to find miR-
206 target genes, which are differentially expressed in each
cancer subtype compared with normal samples.
2.6. Enrichment Annotation Analysis and Network Construc-
tion
FunRich analysis tool version 3 (17) was used for the net-
work construction and the enrichment annotation step.
This software depicts a schematic clusterization of the
gene list with pathway annotations.
3. Results
3.1. Experimentally Validated miR-206 Target Genes
With the purpose of assessment of the sensitivity of
miRNA target prediction tools, we compared the list of ex-
perimentally validated miR-206 target genes with those
predicted by computational algorithms. The lists of experi-
mentally validated miR-206 target genes in all cancer types
and breast cancer as well as the number of bioinformatics
tools predicted each gene are presented in Tables 2 and 3,
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Figure 1. The bioinformatics pipeline used in the current study
Table 1. Summary of miRNA Prediction Tools Used in the Present Study
Target Prediction Tool Organism Features of Tool Website
DIANA Any Conservation, seed match, and free energy http://www.microrna.gr/microT-CDS
miRWalk Human, mouse, and rat Conservation, seed match and free energy http://mirwalk.uni-hd.de/
Target scan Human, mouse, Fly, Fish, and Worm Conservation, seed match http://www.targetscan.org/
PITA Human, mouse, Fly, and Worm Conservation, seed match, free energy, and
site accessibility
http://genie.weizmann.ac.il/pubs/mir07/
Exiqon Human, mouse, and rat Conservation, seed match, and Target-Site
Abundance
https://www.exiqon.com/miRSearch
RNA22 Human, Fruit Fly, Mouse, and Worm Seed match and free energy https://cm.jefferson.edu/rna22/
TargetSpy Human, mouse, rat, Fruit Fly, and Chicken Seed match and site accessibility https://omictools.com/targetspy-tool
MirMAP Human, Chimpanzee, Mouse, Rat, Cow,
Chicken, Zebrafish, and Opossum
Conservation, seed match, and free energy http://mirmap.ezlab.org
Mirbase Human, mouse, rat, worm, and fly Seed match and Target-Site Abundance http://microrna.sanger.ac.uk
MBStar Human Seed match and free energy http://www.isical.ac.in/~ bioinfo_-
miu/MBStar30
Mirza-G Human Conservation, seed match, and site
accessibility
https://omictools.com/mirza-genome-wide-
tool
PACCMIT Any Conservation, seed match, and site
accessibility
http://lcpt.epfl.ch
MirTar2 Human, mouse, rat, dog, and chicken Conservation, seed match, free energy, and
site accessibility
http://mirdb.org
Microrna. org Human, mouse, Fruit Fly, and rat Conservation, seed match, free energy http://www.microrna.org
respectively. CCND1 and CCND2 were predicted as targets of
miR-206 by a high proportion of tools and were also exper-
imentally validated to be targets of this miRNA in diverse
cancer types.
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Figure 2. Flow chart of the protocol used for the search of breast cancer microarray datasets from the GEO database
Table 2. Experimentally Validated Target Genes of miR-206 in All Cancers
Target Gene Number of Tools Predicted the Gene as miR-206 Target Validation Technique Disease Reference
CCND2 10 tools Reporter assay Gastric cancer (18)
MET 8 tools Reporter assay, Western blot, qPCR Rhabdomyosarcoma (19)
GPD2 8 tools Reporter assay, Western blot Many tumor cell lines (20)
G6PD 8 tools Reporter assay, Western blot Many tumor cell lines (20)
CCND1 6 tools Reporter assay, Western blot Different cancer cell lines (21)
CDK4 5 tools Reporter assay Melanoma (22)
PGD 5 tools Reporter assay, Western blot Many tumor cell lines (20)
TKT 3 tools Reporter assay, Western blot Many tumor cell lines (20)
EGFR 3 tools Reporter assay, Western blot, qPCR Lung Squamous Cell Carcinoma (23)
3.2. miR-206 Target Genes Implicated in Breast Cancer
Based on the proposed approach of combining mi-
croarray data analysis and bioinformatics prediction tools,
we identified miR-206 target genes, which are differen-
tially expressed in breast cancer tissues compared with
normal tissues and are possibly implicated in breast can-
cer (Table 4). The high degrees of similarity in expres-
sion profile were observed for SH3GL3, KANK3, and CWF19L2
(overexpressed in all subtypes) and TPM3 (down-regulated
in all subtypes). However, some other genes had a subtype
specific expression profile. For instance, WDR48 and PTPRS
were down-regulated and up-regulated only in luminal B
subtype respectively.
3.3. Network Construction
FunRich tool provided both functional enrichment
and interaction network for miR-206 and associated mR-
NAs. The final dataset obtained from the combinatory
approach was analyzed against 3 different background
databases, namely FunRich, UniProt, and Custom. Figure
3 demonstrates the interaction diagram. Interaction net-
work provided by this tool shows that miR-206 is involved
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Table 3. Experimentally Validated Target Genes of miR-206 in Breast Cancer
Target Gene Number of Tools
Predicted the
Gene as miR-206
Target
Validation
Technique
Reference
ESR1 10 tools Reporter assay,
Western blot, qPCR
(24)
CCND2 10 tools Reporter assay (11)
TWF1 10 tools Reporter assay,
qPCR and Western
blot
(25)
SPRED1 10 tools Reporter assay (26)
VEGF 8 tools Reporter assay (27)
RASA1 8 tools Reporter assay (26)
NRP1 8 tools Reporter assay (28)
SMAD2 8 tools Reporter assay (28)
MAP3K13 6 tools Reporter assay,
qPCR
(29)
CCND1 6 tools Reporter assay (30)
Ncl (Nucleolin) 6 tools Reporter assay,
qPCR and Western
blot
(31)
Tbx3 6 tools Reporter assay (32)
PDCD4 4 tools Reporter assay (33)
CORO1C 4 tools Reporter assay,
qPCR and Western
blot
(34)
PFKFB3 3 tools Reporter assay,
qPCR and Western
blot
(35)
Connexin43 TargetScan and
PicTar
Reporter assay and
qPCR
(10)
in fundamental pathways in breast cancer. The most en-
riched one was TGF-beta pathway.
4. Discussion
The expression pattern analysis of distinct subtypes
of breast cancer might be helpful in the identification of
specific biomarkers as well as the development of person-
alized treatment modalities (36, 37). The role of miRNAs
and their putative targets might be different in each can-
cer type or even among cancer subtypes. In the present
study, we proposed a computational method for the iden-
tification of miR-206 targets in distinct breast cancer sub-
types. Our suggested approach might guide researchers to
arrange their hypotheses of miRNA function on a certain
group of microarray samples to choose the candidate mR-
NAs and miRNAs prior to laboratory experiment. Such ap-
proach would also help in the identification of the role of
predicted targets as tumor suppressor or oncogenes in sig-
naling pathways. In the final list provided by the proposed
approach, there are some genes with expression change in
all breast cancer subtypes as well as some genes with al-
terations in a certain subtype. Such data would help re-
searchers to choose the more suitable cell line for the vali-
dation of miR-206 targets.
MiR-206 targets have been validated in experimental
studies. For instance, in ER positive MCF-7 cell line, lu-
ciferase assays showed that miR-206 decreases cyclinD2 ex-
pression by targeting 2 binding sites in the 3’-UTR of cy-
clinD2 mRNA. The results have been confirmed by qRT-PCR
and Western blot assays (11). Another study in the same cell
line has shown miR-201 inhibitory effect on the expression
of transforming growth factor (TGF)-β, neuropilin-1 (NRP1),
and SMAD2, which participate in migration, invasion, and
EMT in these cells (28). In TN breast cancer cell line, miR-
206 up-regulation has decreased the expression of ma-
trix metalloproteinase (MMP)-2, MMP-9 and increased the
expression level of breast cancer metastatic suppressor
(BRMS)-1. However, luciferase assays showed only GJA1
(Cx43) as a target of miR-206 (10). Considering the com-
plex interaction network between certain miRNA and nu-
merous mRNAs as well as among various mRNAs, the iden-
tification of the net target of each miRNA is of practical
significance. Currently, no high-throughput and low-cost
miRNA target screening method is available. Although
a number of computational methods based on sequence
complementarity of the miRNA and the mRNAs have been
proposed, the predicted interactions using these compu-
tational techniques are unreliable according to high false
positive rates. Incorporation of the expression values of
miRNAs and mRNAs (and/or proteins) has been suggested
as a method to improve the results of sequence-based pre-
dictions (12). Our proposed approach provides a tool for
combination of miRNA target prediction with mRNA ex-
pression data. Although this method is not claimed to
be perfect, the suggested list of targets produced by this
method is anticipated to significantly lessen laboratory ex-
perimental load and the number of interactions to be val-
idated. Homogeneity in experimental conditions should
be maintained in our proposed approach. Considering the
more significant role of other factors such as transcription
factors in regulation of gene expression compared with
miRNAs role, heterogeneity of information sources is re-
garded as a limitation in such approaches (12).
In conclusion, our analysis demonstrated novel mRNA
candidates as probable miR-206 targets, which possibly
participate in the pathogenesis of breast cancer. The gene
list provided by our proposed approach contains some
genes previously validated as miR-206 targets in breast
cancer (CORO1C, TWF1). However, many of the experimen-
tally validated miR-206 targets are not among gene list
provided by our approach. The main cause of such dis-
crepancy is that in our proposed approach, we included
genes with high differential expression between tumor tis-
sues and normal samples to find the most biologically rel-
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Figure 3. The schematic interaction diagram of miR-206-target interactions in breast cancer
evant targets in breast cancer. However, in the experimen-
tal validation of miRNAs targets, the level of expression
change is much lower than our defined level in differen-
tial expression analyses. For instance, in Yin et al.’s study,
the enforced expression of miR-206 resulted in about 50%
reduction in the expression of NRP1 and SMAD2 (28). Fu
et al. (10) observed an approximately similar reduction
in Cx43 levels following the over-expression of miR-206.
However, based on our proposed approach, we considered
300 genes with the most differentially expression between
tumoral and normal samples, which had at least 10 fold
change. Such threshold definition is anticipated to cover
the most biologically relevant mRNA targets. A possible
limitation of our approach is that by using microarray ex-
pression data, miRNA targets can only be detected if the
mRNA is degraded by the miRNA. Therefore, our approach
may leave out some targets that are influenced at the trans-
lation level.
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Table 4. MiR-206 Predicted Target Genes with Differential Expression in Breast Cancer Subtypes Based on the Log2-Transformed Fold Changea
Gene Symbol Gene Description HER2 Triple Negative Luminal A Luminal B Number of Tools Predicted the Gene as miR-206 Target
SH3GL3 SH3 domain containing GRB2 like 3, endophilin A3 * * * * 6 tools
PNP Purine nucleoside phosphorylase # # # 6 tools
CORO1C Coronin 1C # 6 tools
WDR48 WD repeat domain 48 # 6 tools
PTPRS Protein tyrosine phosphatase, receptor type S * 6 tools
SULF1 Sulfates 1 # # # 5 tools
ATP6V1A ATPase H+ transporting V1 subunit A # # # 5 tools
YWHAZ Tyrosine 3-monooxygenase activation protein zeta # # 5 tools
FN1 Fibronectin 1 # # # 5 tools
KIF2A Kinesin family member 2A # 5 tools
RAB5A Member RAS oncogene family # 5 tools
UBE2H Ubiquitin conjugating enzyme E2 H # # # 4 tools
TPM3 Tropomyosin 3 # # # # 4 tools
KDELR2 KDEL endoplasmic reticulum protein retention receptor2 # # 4 tools
SFRP1 Secreted frizzled related protein 1 * 4 tools
TWF1 Twinfilin actin binding protein 1 # 4 tools
FPGT Fucose-1-phosphate guanylyltransferase # 4 tools
SRSF1 Serine and arginine rich splicing factor 1 # 4 tools
GMFB Glia maturation factor beta # # # 3 tools
KANK3 KN motif and ankyrin repeat domains 3 * * * * 3 tools
CALU Calcium-binding protein * * * 3 tools
HOXA5 Homeobox A5 * * 3 tools
VMP1 Vacuole membrane protein 1 # 3 tools
TRIM59 Tripartite motif containing 59 # # # 3 tools
SRPK2 SRSF protein kinase 2 # # 3 tools
PGM5 Phosphoglucomutase 5 * * * 3 tools
MAPK1 Mitogen-activated protein kinase 1 # # # 3 tools
ACTR3 ARP3 actin related protein 3 homolog # # # 3 tools
CWF19L2 CWF19 like 2, cell cycle control * * * * 3 tools
NCBP1 Nuclear cap binding protein subunit 1 # 3 tools
SRSF3 Serine and arginine rich splicing factor 3 # # 3 tools
INMT Indolethylamine N-methyltransferase * * 3 tools
SPTBN1 Spectrin beta, non-erythrocytic 1 * 3 tools
ANP32E Acidic nuclear phosphoprotein 32 family member E # 3 tools
SDPR Caveolae associated protein 2 * 3 tools
AMT Aminomethyltransferase * 3 tools
TBC1D9 TBC1 domain family member 9 # 3 tools
DDX3X DEAD-box helicase 3, X-linked # 3 tools
PREX1 Phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 1 # 3 tools
PCDH19 Protocadherin 19 * 3 tools
ITIH5 Inter-alpha-trypsin inhibitor heavy chain family 5 * * 3 tools
MAPRE1 Microtubule associated protein RP/EB family member 1 # 3 tools
PRPF4B Pre-mRNA processing factor 4B # # # 3 tools
GABRP Gamma-aminobutyric acid type A receptor pi subunit * 3 tools
LMOD1 Leiomodin 1 * * 3 tools
POLR3K RNA polymerase III subunit K # # 3 tools
UCHL5 Ubiquitin C-terminal hydrolase L5 # 3 tools
CA12 Carbonic anhydrase 12 # 3 tools
EDEM3 ER degradation enhancing alpha-mannosidase like pro3 # 3 tools
WISP1 WNT1 inducible signaling pathway protein 1 # 3 tools
RBM47 RNA binding motif protein 47 # 3 tools
FBXO22 F-box protein 22 # 3 tools
ARIH1 Ariadne RBR E3 ubiquitin protein ligase 1 # 3 tools
ZNF146 Zinc finger protein 146 # 3 tools
ARF4 ADP ribosylation factor 4 # 3 tools
IKBKB Inhibitor of nuclear factor kappa B kinase subunit beta # 3 tools
RAB18 RAB18, member RAS oncogene family # 3 tools
NIPBL NIPBL, cohesin loading factor * 3 tools
SS18 nBAF chromatin remodeling complex subunit # 3 tools
ZNF326 Zinc finger protein 326 # 3 tools
a The over- and under-expression are shown by # and * respectively.
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